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ABSTRACT
The number of clinical research investigators whom the Food and Drug Administration (FDA)
has disqualified or totally restricted has been increasing since 1964. In addition, several public
polls and surveys indicate a major dilemma in clinical trial participation and public perceptions
of clinical research. This research investigates how clinical investigator fraud or misconduct
influences public perceptions of participation in clinical trials. To meet this challenge, a welldesigned electronic survey was developed for the faculty at Eastern Michigan University (EMU).
The survey results indicate that 79% of respondents were ―very likely‖ to be influenced by fraud
committed by their own physicians. However, when the fraud has been committed at a hospital
elsewhere, only approximately 20% of respondents reported that they were ―very likely‖ to be
influenced. These results, however, reflect only a select group of people. Further studies on
larger populations are recommended to learn about the impact of investigator fraud on patient
recruitment.

iv

TABLE OF CONTENTS

DEDICATION: ............................................................................................................................... ii
ACKNOWLEDGMENTS ............................................................................................................. iii
ABSTRACT ................................................................................................................................... iv
List of Tables: ............................................................................................................................... vii
List of Figures: .............................................................................................................................. vii
Chapter I: Introduction .................................................................................................................... 1
Chapter II: Background and Problem Statement ............................................................................ 3
Definitions ................................................................................................................................... 3
Early History ............................................................................................................................... 4
Case Studies ................................................................................................................................ 5
Discussion of Public Trust and Confidence ................................................................................ 9
Thesis Statement ....................................................................................................................... 11
Chapter III: Methodology ............................................................................................................. 12
Sample Size Design ................................................................................................................... 12
Research Design ........................................................................................................................ 12
Data Management and Analysis Plan........................................................................................ 14
Human Subjects Protection: ...................................................................................................... 14

v

Chapter 4: Results and Discussion ................................................................................................ 16
Chapter 5: Summary of Findings .................................................................................................. 28
Chapter 6: Conclusion................................................................................................................... 30
REFERENCES ............................................................................................................................. 31
Appendix A: University Human Subject Review Committee (UHSRC) Approval Letter .......... 34
Appendix B: Informed Consent Form / Survey Email ................................................................. 35
Appendix C: Survey Questions ..................................................................................................... 36
Appendix D: The Survey Population Profile ................................................................................ 40

vi

List of Tables:
Table 1 Survey respondents by gender ......................................................................................... 16
Table 2 Survey respondents by age .............................................................................................. 16
Table 3 Survey respondents by expertise...................................................................................... 17
Table 4 Survey respondents by source preferences ...................................................................... 17
Table 5 Clinical Trial Participation: Past & Future ...................................................................... 18
Table 6 Extent of Influence on Decision to Participate: If Fraud Occurs Somewhere in the U.S.19
Table 7 Extent of Influence on Decision to Participate: If Fraud Occurs in Michigan ................ 20
Table 8 Extent of Influence on Decision to Participate: If Fraud Occurs in a Local Hospital ..... 20
Table 9 Extent to Influence Participation: If Fraud By Patient Physician .................................... 21
Table 10 Clinical Trial Participation vs. Extent of Fraud’s Influence .......................................... 22

List of Figures:
Figure 1 Disqualified Clinical Investigators by the FDA (07.15.11) ............................................. 4
Figure 2 Extent of Fraud Influence on Decision to Participate for Category 1 – ―With
Experience‖ by Location............................................................................................................... 24
Figure 3 Extent of Fraud Influence on Decision to Participate for Category 2 – ―Would
Participate‖ by Location ............................................................................................................... 25
Figure 4 Mean values vs. Location of Fraud for Category 1 – ―With Experience‖ and Category 2
– ―Would Participate‖ ................................................................................................................... 26
Figure 5 Average Extent to Fraud Influence by Fraud Location .................................................. 27

vii

Chapter I: Introduction

“While scientific misconduct is rare, when it does occur, it affects public confidence in
the clinical trial process and raises questions about the effectiveness of trial monitoring and its
follow-up by sponsors.” Stan W. Woollen1

“Although the public clearly holds positive attitudes about the general importance of
clinical research, the same cannot be said for public trust in the professionals who oversee,
manage, and support that research.” Kenneth A. Getz2

The two statements above indicate the long-term effects of research misconduct on public
confidence in the clinical research. The first quotation is from a Food and Drug Administration
(FDA) deputy director at a Drug Information Association (DIA) meeting and indicates the major
repercussions of clinical research misconduct and fraud. In the second quotation, Kenneth A.
Getz states that the public has an optimistic perception of clinical trials and their importance in
the advancement of medicine. However, Getz also insists that the public may not have the same
confidence and trust levels in the people who conduct and supervise clinical research studies.
While clinical research organizations have numerous major challenges, patient or subject
recruitment is most crucial. If research misconduct and investigator fraud continue to occur,
there will eventually be a very small percentage of people who have trust in clinical trials.

1

Nevertheless, since 1964, the number of clinical investigators disqualified by the FDA
due to research misconduct has slowly increased, which may show influence on public
awareness of clinical trial knowledge. In addition, polls and surveys conducted by market
research companies have indicated many reasons for public reluctance to participate in clinical
trials (Harris Interactive, 2002). This research study aims to find out how knowledge of
investigator fraud might change public perceptions and whether investigator fraud or misconduct
might affect public participation in clinical trials. If successful, these findings could alter the way
that public awareness campaigns are managed and may lead to a better understanding of the
negative impact of reporting on fraud without proper context.

1

Deputy Director, Division of Scientific Investigations, Center for Drug Evaluation and

Research, FDA - June 14, 2000
2

Founder and Chairman of the Non-Profit Organization CISCRP and a Senior Research Fellow

at the Tufts Center for the Study of Drug Development - ACRP: September, 2008
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Chapter II: Background and Problem Statement
Definitions
Research Misconduct or Fraud:
According to the Office of Research Integrity, U.S. Department of Health and Human
Services and 42 CFR Part 93.103
a. Fabrication is making up data or results and recording or reporting them.
b. Falsification is manipulating research materials, equipment, or processes, or changing
or omitting data or results such that the research is not accurately represented in the
research record.
c. Plagiarism is the appropriation of another person’s ideas, processes, results, or words
without giving appropriate credit.
d. Research misconduct does not include honest error or differences of opinion.
Clinical research misconduct or fraud means, according to the FDA, ―falsification of data
in proposing, designing, performing, recording, supervising, reviewing, analyzing, collecting
clinical research or reporting clinical research results, outcomes and endpoints‖ (Mauriello,
2010).
The FDA uses fraud and misconduct interchangeably and includes acts of omission,
which means consciously not revealing all data and commission which means consciously
altering or fabricating data (Below, March, 2003).
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Early History
The FDA’s various offices regulate all phases of clinical research studies that are
intended to develop evidence to support safety and effectiveness of new or generic
investigational drugs, devices, and biological products. In addition, the FDA has provided
statutes, regulations, and guidance documents for conducting these clinical investigations. All
clinical investigators and other study staff associated with investigations must comply with these
procedures to ensure the integrity of the clinical data. Based on this clinical and non-clinical
data, product approvals are further decided by the FDA.
The FDA’s Office of Regulatory Affairs (ORA) mainly oversees inspections and
enforcement actions, along with other regulatory activities. The ORA has a list of various
categories of clinical investigators who have been completely ―disqualified‖ or ―totally
restricted‖ from clinical investigations, or received necessary ―enforcement actions‖ by FDA due
to non-compliance with regulatory requirements. The graph below shows the number of clinical
investigators per decade in those categories.
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Figure 1 Disqualified Clinical Investigators by the FDA (07.15.11)
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2001-2010

Description of Graph:
The FDA initiated its disqualification process in 1964. The total number of clinical
investigators who were disqualified or totally restricted from clinical investigations between the
years 1964 to 2010 was shown in Figure 1. According to the graph, the number increased
gradually each year, beginning in 1964. From 1964 to 1990, the number of investigators
increased; from 1991 to 2000, on the other hand, the number decreased slightly. From 2001 to
2010, however, this number increased dramatically to 42 investigators.

Case Studies
From the FDA’s disqualified clinical investigators list, three investigator cases were
selected, and the available literature on their misconducts and disqualification was reviewed. The
related information was obtained mainly from the FDA’s warning letters and the media coverage
on those investigators. The investigator (who), his misconducts (what), and the FDA’s response
to the misconducts (how) were presented here as three case studies.
The reason for selecting these case studies was not only that they were renowned, but
also that, in all three cases, the misconduct seems surprising given the researchers’ experience
and prestige of their institutions. Since 1964, the FDA has either disqualified or totally restricted
many other investigators from conducting research-related activities. Some of these
investigators, however, contend that stringent federal regulations were responsible for their
misconduct.
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Case Study 1
Who was the researcher?
Dr. Robert Alan Fiddes, physician, researcher and president of Southern California
Research Institute, Whittier, California.
What was the misconduct?
Beginning in the early 1990s, Dr. Fiddes was involved in over 200 clinical studies and
extensively fabricated and falsified his clinical data. In his studies, fictitious patients were
enrolled, as well as ineligible ones. He also fabricated lab results, by substituting clinical
specimens and manipulating lab instrumentation.
According to the New York Times, ―Dr. Fiddes’s coordinators were paid bonuses for
recruiting patients into the studies. Thereafter they also began improperly enrolling themselves
and members of their family. Over time, the frauds orchestrated by Dr. Fiddes grew ever more
audacious. Eventually, according to government documents, it was not just the records that were
being falsified, instead, the medical tests were rigged -- and at times, patients simply invented.
Outside monitors reviewed the documentation, but since there were real lab records for the
rigged tests, they had no clue that they were being deceived‖ (Kolata, 1999).
The former chief financial officer of Dr. Fiddes’s research center commented in an
interview that Dr. Fiddes was putting the health of all his participants at risk and was skewing
samples that could affect the whole American public.
How was it handled?

6

On June 11, 2002, Dr. Fiddes, along with three of his study coordinators, was debarred
from participation in drug research subject to FDA regulation for 20 years.
Debarment followed upon entry of a guilty plea in a criminal case arising from fraud and
false statements related to several clinical trials.
Dr. Fiddes was sentenced to 15 months in federal prison and ordered to pay $800,000 in
restitution.
The Medical Board of California permanently revoked Dr. Fiddes’s medical license in
2000.
On May 17, 1999, a New York Times headlines read, ―A Doctor’s Drug Trials Into
Fraud.‖
Case Study 2
Who was the researcher?
Dr. J. Michael McGee, physician and practitioner of otolaryngology at University of
Oklahoma, Tulsa, Oklahoma.
What was the misconduct?
As a principal investigator, Dr. McGee conducted clinical trials of an experimental
vaccine for malignant melanoma, in which he failed to fulfill the responsibilities of a clinical
investigator, by violating FDA regulations governing investigational new drugs.
According to the FDA warning letter, Dr. McGee failed to adequately protect the safety
and welfare of human subjects, by enrolling several ineligible subjects in the study and not
obtaining proper Institutional Review Board (IRB) approvals of protocol modifications. In
addition, Dr. McGee was accused of not having exercised control over the investigation, not
7

directly supervising patients who took the investigational drug, and keeping inadequate study
records. Additionally, improper storage of test vaccine may have resulted in its contamination.
Moreover, Dr. McGee did not follow certain protocol requirements, such as removing
from the study severely sick patients who were concurrently undergoing other treatment methods
(the protocol required that such patients be excluded). Worst of all, however, Dr. McGee
concealed adverse side effects data, disclosing it neither to the FDA, the sponsor, nor to the
proper IRBs.
How was it handled?
In January 2009, the FDA permanently debarred and disqualified Dr. McGee from
serving as an investigator in any research.
The FDA field investigator, Cherlynn Mathias said of the fraud: ―It was a perfect lesson
in how not to run a clinical trial.‖
Case Study 3
Who was the researcher?
Dr. Alfred E. Chang, physician, professor and chief of surgical oncology department at
University of Michigan, Ann Arbor, Michigan.
What was the misconduct?
According to the FDA warning letter, Dr. Chang failed to fulfill the responsibilities of a
clinical investigator for studies utilizing unlicensed biological investigational new drugs. The
violations were as follows:
Recruiting subjects who were ineligible to participate in the research
8

Failing to obtain informed consent from the participants in accordance with the
provisions of 21 CFR Part 50, as well as performing study-related procedures prior to
consent from the subjects
Failing to conduct research in accordance with the investigational plan
Failing to follow the protocol in the management of toxicity related to the infusion
Not submitting proper initial and continuing reviews of the clinical studies to the IRB
Failing to maintain adequate and accurate records of the disposition of investigational
drugs and case histories of individuals treated with investigational drugs
How was it handled?
On April 7, 2010, the FDA permanently debarred and disqualified Dr. Chang from
serving as an investigator in any research.

Discussion of Public Trust and Confidence
Although various acts, regulations, and guidance documents are available to serve the
clinical investigation process, research misconduct remains a persistent problem. The rise in the
number of investigators disqualified or totally restricted each year influences the general public’s
perceptions of clinical trials. Currently, most clinical research organizations depend on the
Internet and social media for promotions and patient recruitment. Yet these very tools have been
responsible for spreading research misconduct. In addition, people’s awareness of clinical trials
is influenced by word-of-mouth publicity. This may adversely affect public perceptions about
volunteering or participating in a clinical trial.
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The Harris Interactive group, a market research company, has conducted numerous
surveys and public opinion polls regarding clinical trials and has presented significant findings
regarding public opinion. First, a survey study conducted in 2008 indicated that most practicing
physicians usually fail to follow clinical guidelines (Harris Interactive , 2008). In addition, this
survey strongly suggests that financial incentives to physicians might have encouraged
physicians to follow these guidelines. Secondly, another study conducted in 2007 showed that
public confidence and trust in the clinical research enterprise has gradually decreased (Harris
Interactive , 2007). Moreover, a study conducted in 2002 revealed that a majority of people do
not agree with how patients were treated in clinical trials (Harris Interactive, 2002). Finally, a
nationwide survey conducted by a non-profit organization called the Center for Information and
Study on Clinical Research Participation (CISCRP) uncovered that only a small percentage of
participants considered clinical trials to be safe (Surveys on Public Opinion on Clinical Research,
2004 to 2008).
One challenge of clinical research is to persuade people that they will not suffer as a
result of participating. Historical research misconduct cases such as Nuremberg trials (1948),
Thalidomide tragedy (1962), and the Tuskegee syphilis study (from 1932 to 1972) have had
negative effects on public confidence in clinical research. The current surveys and public polls
reveal a dilemma in the public perception of clinical trials. So the present research will focus on
clinical research investigator fraud’s possible effect on the public and to find out how it
influences participants’ opinions of clinical trials.

10

Thesis Statement
An attempt will be made to answer these following questions:
Specific Aim / Problem Statement:
1. How might fraud on the part of clinical research investigators influence the
participants’ perception and likelihood of participating in clinical studies?

Hypothesis:
Knowledge of fraud committed by clinical research investigators affects people’s
perception of clinical trials and their likelihood of participating in them.
Geographic proximity of fraud cases may contribute to people’s reluctance to
participate in clinical trials.

2. Do factors such as socio-demographics, education level, general health knowledge,
and previous clinical study experiences influence the public’s perception of
participation in clinical studies?

Hypothesis:
The awareness of clinical research knowledge varies depending on a participant’s
socio-demographics, education level, general health knowledge, or previous
clinical trial experience. However, it is not expected that socio-demographic
factors will significantly affect the influence of investigator fraud on people’s
likelihood to participate in clinical trials.
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Chapter III: Methodology
Sample Size Design
This research has been conducted in order to determine how fraud by clinical research
investigators might influence public perceptions and a person’s likelihood to participate in
clinical trials. Assessing the role of geographic proximity to investigator fraud is also part of the
study objectives. To meet these research goals, a well-designed electronic survey was developed
to obtain the views of faculty within Eastern Michigan University (EMU). The population of
interest for this study was faculty employed by Eastern Michigan University.
There are approximately 1,396 faculty members at EMU. These include 692 regular
faculty, 97 lecturers and 607 adjunct faculty members. The faculty data (as of 2011) was
obtained from EMU’s Institutional Research and Information Management (IRIM) department.
All of these faculty members were sent an electronic survey with opinion questions having a
five-point Likert rating scale.

Research Design
Pre-Study Phase
Power analysis to determine appropriate sample size
Extensive review of literature on research misconduct and clinical investigator fraud
Develop study design, questionnaire, informed consent, and intervention plan
Approval from thesis committee and EMU’s University Human Subjects Review
Committee (UHSRC)
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Study Phase
The descriptive quantitative method of research design was developed for this research
survey. Defining descriptive research, Creswell (1994) stated that ―the descriptive method of
research is to gather information about the present existing condition‖ (Creswell, 1994). The
descriptive method of research is also used to describe the nature of a current situation or
condition and to explore its causes. Moreover, it is flexible, quick, and appropriate for this
survey, as this method is used for gathering prevailing conditions.
The eligibility criteria for this survey research consist of:
Inclusion Criteria:
a. Age 21 or over (EMU faculty)
Exclusion Criteria:
b. Non-EMU faculty
The EMU faculty was selected as the target population for this study. Following approval
by the UHSRC (Appendix A), an electronic mail (e-mail) was sent to all participants. The
UHSRC-approved informed consent document (Appendix B) was used as the content of the
email, briefly describing the study procedures and requesting recipients’ participation. The
survey questionnaire (Appendix C) was used as the main and primary data gathering source for
this study. In the survey questions, the participants were asked five study-related questions,
followed by five response options, involving a case scenario of a disease or condition.
Additionally, the participants were asked four general demographic questions. The five response
options represented, for each question, the extent to which clinical investigator fraud was likely
to influence the respondent.
13

Data Management and Analysis Plan
Two weeks after sending out the survey, the survey was closed and the study data
analysis phase began. The primary data analysis included all data collected from the respondents
within this two-week period. To preserve anonymity, the survey database did not collect any
information or data (such as Internet Protocol (IP) addresses) that might identify participants.
After obtaining the completed surveys from the participants, responses for each question
were obtained and tabulated. From the responses, percentages for each response were calculated.
The average weighted mean and standard deviation values were calculated for Likert scale
questions.
Based on the responses to first survey question, the other four study-related questions
were cross tabulated. The cross tabulated information provided a clear method of understanding
results qualitatively and quantitatively and for examining the study hypothesis.

Human Subjects Protection
According to the Code of Federal Regulations, 45 CFR 46 entitled ―Protection of Human
Subjects,‖ research projects involved with use of human subjects are subject to federal policies.
As this research involves human subjects participation (specifically, among the EMU
population), this study falls under federal regulations. This research complies with all applicable
regulations in all cases of survey procedures involving human subjects.

Institutional Review Board (IRB)
Appropriate notification and approval from the IRB was obtained before proceeding with
any study-related activities. The research proposal, survey instruments, and informed consent
14

document were submitted to and approved (Appendix A) by the University Human Subjects
Review Committee (UHSRC) at Eastern Michigan University.

Informed Consent Form (ICF):
Every selected study participant received an informed consent document (Appendix B).
The consent form clearly explained the study purpose, procedures, voluntariness, and contact
information. The informed consent form was mailed electronically to all selected participants,
since this was an electronic survey. Finally, the survey questions were free from all materials that
might alter participant perceptions.
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Chapter IV: Results and Discussion
Demographics of Respondents
A total of 156 people out of 1396 responded to the survey for a response rate of 11.2%.
The response rate also varies by colleges (Appendix D). In addition to the five study-related
questions, the respondents were asked four optional demographics questions: their gender, their
age, their college of the university, and their preferred sources of health care information (the last
question allowed for more than one response). Only three participants refused to provide their
demographic information.
The four tables below present tabulations of the demographics responses.
Gender
Table 1 Survey respondents by gender

#

Answer

Response

%

1

- Male

61

40%

2

- Female

92

60%

Total

153

100%

Response

%

Age
Table 2 Survey respondents by age

#

Answer

1

- 21 to 30

8

5%

2

- 31 to 40

22

14%

3

- 41 to 50

38

25%

4

- 51 and above

84

55%

Total

152

100%

16

College of University
Table 3 Survey respondents by college of University

#
1

Answer
- College of Arts and Sciences

Response
66

%
43%

2

- College of Business

11

7%

3

- College of Education

20

13%

4

- College of Health and Human
Services

33

22%

5

- College of Technology

16

10%

6

- Other

7

5%

153

100%

Total

Most Trusted Sources for Health Related Information:
Table 4 Survey respondents by source preferences

#
1

Answer
- Physicians (Surgeons or
Doctors)

Response

%

134

88%

2

- Print media, e.g., newspapers,
magazines

45

29%

3

- Broadcasting media, e.g.,
television, movies,
documentaries

23

15%

4

- Social networking media, e.g.,
Facebook, MySpace, Twitter,

0

0%

13

8%

118

77%

72

47%

29

19%

5

6
7

- General Internet media, e.g.,
news websites, discussion
forums
- Health specific Internet
media, e.g., medical news sites,
medical discussion forums
- Friends and/ Family members

8
- Other
Note: Multiple Response Question
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Presentation of Research Question Responses:
The five tables and charts below present the responses to the five research questions.
Q-1: Clinical Trial Participation - Past and Future:
From question 1, participants’ prior clinical trial opportunities, experience, and likelihood
to participate in future clinical trials were obtained.
According to results in Table 5, 20% of respondents had previous clinical trial
experience, and 61% of those respondents would be willing to participate in the future, given the
opportunity. On the other hand, 10% of respondents had had opportunities to participate but had
chosen not to. And the remaining 10% of respondents would not consider participating, even in
the future.
Table 5 Clinical Trial Participation: Past & Future

# Answer
Those who had an opportunity and
participated in clinical trials
Those who had an opportunity but DID
2
NOT participate
1

Response

%

31

20%

15

10%

3

Those who NEVER had an opportunity,
but will consider participating

95

61%

4

Those who NEVER had an opportunity,
and WILL NOT consider participating

15

10%

156

100%

Total
Base: All Adults (age: 21 and above)
Q-2: Fraud Occurring Somewhere in U.S.

Question 2 captures participant perceptions on the influence of investigator fraud on a
clinical study conducted somewhere in United States.
18

From Table 6, it appears that 45% respondents report that investigator fraud somewhere
in United States would ―not likely‖ influence them. Conversely, the second-largest portion of
respondents (21%) said fraud would ―very likely‖ influence them.
Table 6 Extent of Influence on Decision to Participate: If Fraud Occurs Somewhere in the U.S.

# Answer
1 - Not likely

Response
69

%
45%

2 - Less likely

18

12%

3 - Somewhat likely

23

15%

4 - Moderately likely

12

8%

5 - Very likely

33

21%

155

100%

Total

Q-3: Michigan Investigator Fraud
The third question in this series asked about the extent to which respondents would be
influenced by investigator fraud committed in the state of Michigan.
Table 7 displays the percentages for all responses. In this case, 35% of respondents
reported that Michigan investigator fraud would ―not likely‖ influence their decision to
participate in local clinical trials, whereas 23% of respondents reported that Michigan
investigator fraud would ―very likely‖ influence them. This type of fraud was ―somewhat likely‖
to influence 17% of respondents, and 15% of respondents answered ―less likely.‖
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Table 7 Extent of Influence on Decision to Participate: If Fraud Occurs in Michigan

# Answer
1 - Not likely

Response
54

%
35%

2 - Less likely

23

15%

3 - Somewhat likely

26

17%

4 - Moderately likely

16

10%

5 - Very likely

35

23%

154

100%

Total

Q-4: Local Hospital Investigator Fraud
The influence of local hospital investigator fraud on the decision to participate in a
clinical trial conducted by another investigator was obtained from question 4.
The results demonstrated in Table 8 were quite interesting. Misconduct or fraud by an
investigator at a local hospital would ―not likely‖ influence 21% of respondents in deciding
whether to participate in a clinical study by another investigator. Nevertheless, it would ―very
likely‖ influence 21% of respondents and ―moderately likely‖ influence 22%. In addition, this
misconduct would ―less likely‖ influence 21% and ―somewhat likely‖ influence the remaining
21%. Responses to this question were dispersed almost uniformly among all five options.

Table 8 Extent of Influence on Decision to Participate: If Fraud Occurs in a Local Hospital

# Answer

Response

%

1 - Not likely

32

21%

2 - Less likely

28

18%

3 - Somewhat likely

27

18%

4 - Moderately likely

34

22%

5 - Very likely

33

21%

154

100%

Total

20

Q-5: Research Fraud by Patient Physician
The influence of fraud committed by a patient physician on respondents’ likelihood to
participate a clinical trial was determined from the last question.
Table 9 shows that fraud committed by a patient physician would ―very likely‖ influence
79% of respondents. In addition, this type of misconduct would ―moderately likely‖ influence
6%, ―somewhat likely‖ influence 5%, and ―less likely‖ influence 1%. This fraud would ―not
likely‖ influence 8% of respondents. From the results, it appears that fraud committed by a
patient physician is more likely to influence clinical trial participation than other locationdetermined frauds.
Table 9 Extent to Influence Participation: If Fraud Is From Patient Physician

# Answer

Response

%

1 - Not likely
2 - Less likely

13
2

8%
1%

3 - Somewhat likely

7

5%

4 - Moderately likely

10

6%

5 - Very likely

122

79%

154

100%

Total

4.3 Cross Tabulation of Results
The survey respondents can be grouped according to the four major special classes of
participation. It is illustrative to cross tabulate the results of these four classes of respondents,
since their responses to other misconduct/fraud questions differ appreciably on certain fraud
questions as shown in Table 10.
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Table 10 Clinical Trial Participation vs. Extent of Fraud’s Influence

Q1: Clinical Trial Participation
With
Experience

Would
Participate

Didn't
Participate

Wouldn't
Participate

18
7

37
10

8
1

6
0

69
18

Somewhat likely
Moderately likely

3
2

18
6

1
2

1
2

23
12

Very likely

1

23

3

6

33

Total
Not likely
Less likely

31
15

94
29

15
7

15
3

155
54

Somewhat likely

4
6

15
16

2
2

2
2

23
26

Moderately likely
Very likely

4
1

9
25

0
4

3
5

16
35

Total

30

94

15

15

154

10
6

17
18

2
3

3
1

32
28

7

14

5

1

27

Very likely

4
3

24
21

1
4

5
5

34
33

Total

30

94

15

15

154

2
1

5
1

3
0

3
0

13
2

Moderately likely

2
1

5
6

0
0

0
3

7
10

Very likely

24

77

12

9

122

Total

30

94

15

15

154

Fraud/Misconduct- Response
Q2: Somewhere
Not likely
in U.S.
Less likely

Q3: Michigan

Q4: Local
Hospital

Not likely
Less likely
Somewhat likely
Moderately likely

Q5: Patient
Physician

Not likely
Less likely
Somewhat likely

Total

Table 10 Explanation
Cross tabulated information among all five research questions presents an idea of data
distribution among participants. The above table differentiates responses of all participants
depending on their likelihood to participate in clinical trials.
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From the table, three major categories of respondents were chosen for discussion.
Category 1 includes those participants who initially participated in clinical trials. Given their
experience in clinical trials, their responses to fraud/misconduct-related questions are significant.
Category 2 includes those participants who would consider participating in future clinical trials if
given the opportunity. Category 3 consists of those participants who have neither participated in
the past nor wish to participate in the future. This latter category will not be discussed further for
data analysis.

Category 1 - ―With Experience‖
Of those responding, 20% were category 1 respondents—individuals who had
participated in clinical trials before. The investigator misconduct/fraud somewhere in U.S. would
not likely influence 58% of category 1 respondents. It would very likely influence 3% of category
1 respondents, which in this case means only one respondent. Investigator misconduct/fraud in
Michigan would not likely influence 50% of category 1 respondents and would very likely
influence 3% (again, only one respondent). Fraud in a local hospital would not likely influence
34% and would very likely influence 10% of category 1 respondents. Fraud committed by a
consulting physician would very likely influence 80% of category 1 respondents and would not
likely influence 7%. In sum, it appears that research fraud is not likely to influence most category
1 respondents, unless it is committed by the patient physician; research fraud by a patient
physician is very likely to influence most of the category 1 respondents.
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Graphical Presentation:
The graph presents the distribution of survey responses for each fraud location. The
graphs were drawn between the percentages (%) of each category of respondents and their
responses regarding the influence of investigator fraud.
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Figure 2 Extent of Fraud Influence on Decision to Participate for Category 1 (―With Experience‖) Participants by Location

Category 2 - ―Would Participate‖
The survey respondents who would consider participating in future clinical trials
(category 2) account for 61% of total respondents. Investigator misconduct occurring somewhere
in U.S. would not likely influence 40% of category 2 respondents, whereas 25% said fraud would
very likely influence them. In cases of fraud in the state of Michigan and in a local hospital,
category 2 respondents’ answers differed. Fraud occurring in Michigan would not likely
influences 30% of respondents, while 27% said it would very likely influence them, and 17%
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said less likely. In contrast, fraud in a local hospital was not likely to influence 18%, less likely to
influence 19%, somewhat likely to influence 15%, moderately likely to influence 26%, and very
likely to influence 22% of respondents. Fraud by a patient physician was very likely to influence
82% of category 2 respondents and moderately likely to influence 6.4%. Fraud committed by a
patient physician would not likely influence 5.3% of respondents. In sum, the majority of
category 2 respondents said fraud committed by a patient physician would very likely influence
them, while fraud somewhere in U.S. was not likely to influence them.
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Figure 3 Extent of Fraud Influence on Decision to Participate for Category 2 (―Would Participate‖) Participants by Location

Comparing Means for Category 1 – ―With Experience‖ and Category 2 – ―Would Participate‖
The above graphs indicate the distribution of investigator fraud influence based on the
location of the fraud. However, the likelihood of investigator fraud influence on a respondent’s
decision to participate in clinical trials was determined by calculating the mean of each section of
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response, since the extent to which investigator fraud influenced respondents changed in each
case, depending on the location of the investigator or fraud.
Since these survey questions were designed and developed using a 1 (not likely to
influence) to 5 (very likely to influence) Likert scale for responses, the mean for each question
could be determined. Finally, the extent of investigator fraud influence in each of the four
situations presented—somewhere in the U.S., in Michigan, in a local hospital, and by a
consulting physician—was obtained. A graph drawn between category 1 and category 2, with
these calculated mean values of fraud influence (with scale on Y-axis: 1-not likely, 2-less likely,
3-somewhat likely, 4-moderatelty likely and 5- very likely), gives an exact and final distribution
of investigator fraud influence.

Category1

5

Category2
4.6
4.5

4
Mean
Values 3
2

2.6

3.1

2.8

2.5

2.1
1.7

1
United States

Michigan

Local Hospital

Consulting Physician

Proximity or Location of Fraud

Figure 4 Mean values vs. Location of Fraud for Category 1 (―With Experience‖) and Category 2 (―Would Participate‖)
Participants
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Category 1 vs. Category 2
Of the 33 respondents who said fraud occurring somewhere in U.S. would very likely
influence them, 70% were in Category 2. Of the 35 respondents who said fraud in Michigan
would very likely influence them, 71.4% were respondents from Category 2. Likewise, of the 34
respondents who reported that fraud in a local hospital would moderately or very likely influence,
the majorities were in Category 2. The Category 1 responses to cases involving fraud committed
in Michigan or somewhere in the U.S were constant, differing in fraud cases occurring in a local
hospital or involving a consulting physician.
Mean Fraud Extent for All Respondents
The mean values were calculated using the 1-not likely to 5-very likely scale. The graph
drawn between mean values vs. locations of investigator fraud did not give a consistent increase
in the slope, as expected in the hypothesis. However, from the graph it appears that the average
likelihood of fraud influence gradually increased, the closer the proximity of the fraud.
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Figure 5 Mean Extent of Fraud Influence by Fraud Location
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Consulting Physician

Chapter V: Summary of Findings
The participants in this survey research were faculty members at Eastern Michigan
University. As stated in the methodology section, these faculty members included lecturers and
adjuncts of Eastern Michigan University. This suggests that all of the respondents were well
educated and held doctorates and/or master’s degrees. In addition, the population was diverse,
including faculty from all colleges within the university. The majority of respondents (81%)
were age 41 and above, and 55% of this segment were over 50.
From the survey results, respondents considered physicians the most trustworthy source
of health-related information, followed by health-specific Internet media (such as medical news
sites and medical discussion forums), family and friends, and, finally, print media. Social
networking media, on the other hand, was not selected by a single participant as a trusted source
for health related information.
The majority of survey respondents stated that they would consider participating in other
clinical trials, given the opportunity. Knowledge of fraud, irrespective of where it occurred,
would discourage 25% of this group from participating in clinical trials. Therefore, it seems that
knowledge of investigator fraud or misconduct, regardless of where it occurred, may very likely
discourage the general public from participating in clinical trials. In addition, as investigator
fraud occurs geographically closer to the respondents, they gradually grow less inclined to report
that the fraud would not likely influence them. Of respondents who were interested in
participating in clinical trials, 40% said that fraud occurring somewhere in U.S. would not likely
influence them. The closer the geographic proximity of the fraud, the less often respondents
reported that knowledge of the fraud would not likely influence them: 31% if the fraud occurred
in Michigan, 18% if the fraud in occurred in a local hospital, and only 5% if their own physician
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committed the fraud. Again, these values suggest that the location of a known instance of fraud
affects respondents’ willingness to participate in clinical trials. It is not geography, however, but
the knowledge of fraud and of who committed it, that discouraged respondents from participating
in clinical trials.
Wherever it may occur, research investigator fraud influences people’s likelihood to
participate in clinical trials. Those who have already participated in clinical trials were nearly
consistent about their decision to participate, when they heard about the investigator fraud. The
perceptions of those who had never before participated but would consider participating in future
changed with any fraud knowledge and also changed rapidly with their investigator fraud. On the
other hand, the results represented people’s immediate reaction to learning of investigator fraud.
But how long this fraud knowledge will have the public/participant attention was another
important research question to consider. Hence, further studies are recommended to study the
time of impact.
From the results outlined above, it appears that as the location of the investigator fraud
approaches the location of the individual, its likelihood to influence that individual’s decision to
participate in clinical trials also increases. Therefore, we see the public’s likelihood to participate
in clinical trials decreasing. However, the differences among the averages were small in cases of
fraud occurring somewhere in the United States, in Michigan, and in a local hospital. The
influence of fraud in these three cases is mild compared to the last case—fraud committed by a
patient physician. The influence of research investigator fraud or misconduct may depend on the
location of the fraud, and this geographical impact is less compared with knowledge of fraud
committed by a patient physician.
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Chapter VI: Conclusion
Patient recruitment and retention is a constant challenge for clinical research
organizations. To rise to this challenge, every organization must secure and maintain public trust
and confidence in clinical research. The current results from this pilot study show that
knowledge of investigator fraud has greater impact on the participant’s perceptions than
knowledge of where the fraud occurred.
The present findings address only a select group of highly educated members of the
community. Further studies involving larger populations are recommended to learn more about
clinical research investigator fraud and its influence on the public perception of
clinical trials. In addition, further studies are necessary for developing and organizing new
clinical awareness strategies, in order to earn back public trust and confidence in clinical trials.
Additional data will also be necessary to extrapolate to other populations and to discover the
transient nature of fraud impact on recruitment to studies.
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Appendix A: University Human Subject Review Committee (UHSRC) Approval Letter
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Appendix B: Informed Consent Form / Survey Email
Dear faculty member,
As a part of my master’s thesis, I would like to request your participation in a survey research.
You have been selected by the Eastern Michigan University to complete this survey about
research investigator (physician) fraud or misconduct in clinical trials. Participation in this study
is completely voluntary and you may choose to quit the survey at any time. Please be assured
that your answers are anonymous. No Individuals response to the survey will ever be identified
in any report. All data will be compiled in the aggregate, and no individual respondents will be
identified. This survey (six multiple choice questions) will take you approximately 5 to
10 minutes to complete. There is no known risk involved with your participation.
Web Survey-Link: https://umichumhs.qualtrics.com/SE/?SID=SV_0juiXIZXsmOL79O
By clicking on the link above, you are indicating your consent to participate in this survey.
There is no direct benefit in your participation but your input is valued and I hope you will
respond. If you have any questions or concerns about the study, I encourage you to contact Irwin
Martin Ph.D., Associate Professor, College of Health and Human Services, Marshall
Building, imartin2@emich.edu.
“This research protocol and informed consent document has been reviewed and approved
by the Eastern Michigan University Human Subjects Review Committee for use from
10.17.2011 to 10.31.2011. If you have questions about the approval process, please
contact Dr. Gretchen Dahl Reeves, PhD, Chair, CHHS Human Subject Review Committee
at 734.487.0077”
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Appendix C: Survey Questions
Case Scenario:
“You have a disease or condition.
You are being treated adequately, but improvement is possible.
You are informed of a clinical study of a new, but not yet approved drug.”

Q-1: Have you ever had an ―opportunity to participate‖ or to volunteer in any clinical study
before?
-

Yes. And, I agreed to participate in a clinical study

-

Yes. But, I did not agree to participate

-

No. I never had an opportunity. But, I would consider participating

-

No. I never had an opportunity. And, I would not consider participating

Q- 2: Suppose that you learned that an investigator in ―another part of the U.S.‖ was involved in
research misconduct*. To what extent would this misconduct influence your decision to
participate in a clinical study conducted locally?
-

Not likely

-

Less likely

-

Somewhat likely

-

Moderately likely

-

Very likely

*Misconduct may include actions such as falsification of data or improper consent of subjects
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Q- 3. Suppose that you learned that an investigator ―from Michigan‖ was involved research
misconduct*. To what extent would this misconduct influence your decision to participate in a
clinical study conducted locally?
-

Not likely

-

Less likely

-

Somewhat likely

-

Moderately likely

-

Very likely

*Misconduct may include actions such as falsification of data or improper consent of subjects

Q- 4: Suppose that you learned that an investigator ―from your local hospital‖ was involved in
research misconduct*. To what extent would this misconduct influence your decision to
participate in a clinical study conducted by ANOTHER investigator?
-

Not likely

-

Less likely

-

Somewhat likely

-

Moderately likely

-

Very likely

*Misconduct may include actions such as falsification of data or improper consent of subjects
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Q- 5: Suppose that ―your physician‖ was involved in research misconduct*. To what extent this
would influence your decision to participate?
-

Not likely

-

Less likely

-

Somewhat likely

-

Moderately likely

-

Very likely

*Misconduct may include actions such as falsification of data or improper consent of subjects

Q-6: Demographic Questions:
Q-6a: What is your gender?
-

Male

- Female

Q-6b: What is your age?
-

21 to 30

- 31 to 40

- 41 to 50

Q-6c: In which college do you teach or research primarily?
-

College of Arts and Sciences

-

College of Business

-

College of Education

-

College of Health and Human Services

-

College of Technology

-

Other (Please specify)
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- 51 and above

Q-6d: With respect to health related information, what are your trusted sources of information?
(Check all that apply)
-

Physicians (Surgeons or Doctors)

-

Print media, e.g., newspapers, magazines

-

Broadcasting media, e.g., television, movies, documentaries

-

Social networking media, e.g., Facebook, MySpace, Twitter,

-

General Internet media, e.g., news websites, discussion forums

-

Health specific Internet media, e.g., medical news sites, medical discussion forums

-

Friends and/ Family members

-

Other (Please specify)
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Appendix D: The Survey Population Profile

The Survey Population Profile by their Colleges (2011 data)
#

College

1

College of Arts and Sciences

2
3

Faculty

Lecturers

Adjuncts

Total

%

363

51

319

733

9.0%

College of Business

73

10

37

120

9.2%

College of Education

90

18

61

169

11.8%

89

13

118

220

15.0%

College of Health and Human
4
Services
5

College of Technology

54

3

62

119

13.4%

6

Other

23

2

10

35

20%

Total

692

97

607

1396

% means, the survey response rate with respect to each college
(Source: Institutional Research and Information Management (IRIM), EMU)
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